Pharmaceutical Products
218600-53-4;Bardoxolone methyl ;NSC 713200; RTA 40
218600-53-4;Bardoxolone methyl ;NSC 713200; RT
Description
Bardoxolone methyl(NSC 713200; RTA 402; CDDO Methyl ester) is the lead molecule in Reata& acute;s portfolio of Antioxidant Inflammation Modulators (AIMs). The AIMs are potent inducers of the transcription factor Nrf2, an important biological target that controls the production of many of the body& acute;s antioxidant and detoxification enzymes. Because oxidative stress and inflammation occur throughout the course of chronic kidney disease (CKD) and are known to contribute to loss of kidney function, agents that activate the Nrf2 pathway in patients with CKD may provide a novel method for preserving or improving kidney function. Bardoxolone methyl(NSC 713200; RTA 402; CDDO Methyl ester) is currently being investigated as a potential oral once-a-day treatment for CKD.
http://www.chemscene.com/Bardoxolone-methyl.html
Read More
ChemScene, LLC
ChemScene Pharmaceutical chemical
Address: 11 Deer Park Drive, Suite 102A, Monmouth Junction, NJ 08852,
jersey, new jersey
United States, 07097
Tel: 732-484-9848
Fax:
